| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Radiomics signature: A potential biomarker for β-arrestin1 phosphorylation prediction in hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Feng Che, Qing Xu, Qian Li, Zi-Xing Huang, Cai-Wei Yang, Li-Ye Wang, Yi Wei, Yu-Jun Shi and Bin Song |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81971571 |
| Science and Technology Support Program of Sichuan Province |
2021YFS0144 |
| Science and Technology Support Program of Sichuan Province |
2021YFS0021 |
| China Postdoctoral Science Foundation |
2021M692289 |
|
| Corresponding Author |
Bin Song, MD, Chief Doctor, Doctor, Doctor, Professor, Department of Radiology, West China Hospital, Sichuan University, No 37, GUOXUE Alley, Wuhou district, Chengdu 610041, Sichuan Province, China. songlab_radiology@163.com |
| Key Words |
Hepatocellular carcinoma; Sorafenib resistance; β-Arrestin1 phosphorylation; Radiomics; Computed tomography; Overall survival |
| Core Tip |
The aim of this study was to develop and validate radiomics-based models for predicting β-arrestin1 phosphorylation in hepatocellular carcinoma (HCC). A total of 99 HCC patients (training cohort: n = 69; validation cohort: n = 30) were included, and the final clinico-radiological-radiomics model integrating the radiomics scores and clinico-radiological risk factors showed satisfactory discriminative performance (AUC = 0.898, 95%CI, 0.820 to 0.977). The preoperative prediction model can be used as a noninvasive and effective tool to help predict the outcome of HCC patients treated with sorafenib and identify patients who would benefit most from sorafenib treatment. |
| Publish Date |
2022-04-06 08:50 |
| Citation |
Che F, Xu Q, Li Q, Huang ZX, Yang CW, Wang LY, Wei Y, Shi YJ, Song B. Radiomics signature: A potential biomarker for β-arrestin1 phosphorylation prediction in hepatocellular carcinoma. World J Gastroenterol 2022; 28(14): 1479-1493 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i14/1479.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i14.1479 |
